300347 泰格医药
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,660,204-8.00%7,384,0397,085,4715,213,5383,192,279
减:营业总成本1,305,288-4.04%5,554,1255,156,5443,637,7652,420,862
    其中:营业成本1,032,081-5.23%4,535,5114,277,0082,942,8831,678,036
               财务费用(21,920)37.34%(108,324)(158,124)(216,363)88,052
               资产减值损失(7,752)41.16%(29,725)(2,416)(12,915)5,414
公允价值变动收益12,753-92.77%352,771535,8571,815,3901,137,889
投资收益(3,591)-113.93%338,175102,751312,283283,773
    其中:对联营企业和合营企业的投资收益----105,18339,76314,348(3,508)
营业利润362,196-42.59%2,486,9412,582,3993,696,9672,222,312
利润总额362,364-42.58%2,488,5332,585,3773,684,5662,218,707
减:所得税费用49,794-20.63%338,606313,652292,864189,707
净利润312,570-45.00%2,149,9272,271,7253,391,7022,029,001
减:非控股权益77,498-59,975.46%125,077265,173517,539279,226
股东净利润235,072-58.65%2,024,8502,006,5522,874,1631,749,775

市场价值指针
每股收益 (元) *0.270-59.09%2.3402.3203.3102.200
每股派息 (元) *----0.5680.5500.5000.300
每股净资产 (元) *24.2224.90%24.10222.44720.77418.474
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容